Long-Term Assets: The sum of all assets classified as non-current.
Lineage Cell Therapeutics, Inc. (LCTX) had Long-Term Assets of $61.77M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$1.50M |
|
$-4.14M |
|
$0.04M |
|
$1.47M |
|
$8.01M |
|
$-6.50M |
|
$2.36M |
|
$-4.14M |
|
$-4.14M |
|
$-4.14M |
|
$-4.14M |
|
$-4.14M |
|
$-4.14M |
|
$-6.50M |
|
$-6.34M |
|
226.05M |
|
226.05M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$49.98M |
|
$2.15M |
|
|
Long-Term Assets |
$61.77M |
$111.75M |
|
$13.09M |
|
$0.05M |
|
$21.01M |
|
$34.10M |
|
$77.66M |
|
$20.44M |
|
$77.66M |
|
228.36M |
|
| Cash Flow Statement Financials | |
$-4.89M |
|
$1.90M |
|
$5.04M |
|
$46.35M |
|
$48.34M |
|
$1.99M |
|
$1.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.82 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
97.60% |
|
-433.09% |
|
-433.09% |
|
-- |
|
-275.83% |
|
-275.57% |
|
$-4.98M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
7.05 |
|
12.76 |
|
-5.34% |
|
-20.27% |
|
-3.71% |
|
-5.33% |
|
$0.34 |
|
$-0.02 |
|
$-0.02 |
|